雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Three-month results of intravitreal injection of ranibizumab BS for macular edema associated with retinal vein occlusion Asuka Nakamura 1 , Yoshihito Sakanishi 1 , Tatsuya Fujii 1 , Meiko Kimura 1 , Ayumi Ouchi 1 , Nobuyuki Ebihara 1 1Department of Ophthalmology, Juntendo University Urayasu Hospital pp.998-1004
Published Date 2025/8/15
DOI https://doi.org/10.11477/mf.037055790790080998
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:To evaluate the 3-month outcomes of intravitreal injection of Ranibizumab BS(IVRBS) for macular edema associated with retinal vein occlusion(RVO-ME).

Subjects and Methods:This study included patients treated with IVRBS for RVO-ME at Juntendo University Urayasu Hospital. The injection regimen comprised one initial IVRBS, followed by follow-up visits after one week and monthly thereafter. Re-treatment was performed when the central macular thickness(CMT) exceeded 300 μm and macular edema(ME) recurred or persisted. A retrospective review was conducted using medical records to assess logMAR visual acuity, CMT changes, and time to recurrence of Branch Retinal Vein Occlusion(BRVO) and Central Retinal Vein Occlusion(CRVO) over 3 months following the first injection.

Results:The study included 9 eyes of 9 patients with BRVO(mean age 71.4±5.9 years) and 9 eyes of 9 patients with CRVO(mean age 66.6±20.2 years). Baseline visual acuity and CMT were BRVO at logMAR 0.47±0.36 and 479.8±127.7 μm and CRVO logMAR 0.46±0.40 and 662.8±279.5 μm. At 3 months after the initial injection, for BRVO, visual acuity improved to 0.19±0.19, and CMT decreased to 235.7±68.7 μm, indicating significant improvement compared to baseline(p=0.014, p=0.0078). For CRVO, visual acuity was 0.40±0.40, and CMT was 438.3±215.1 μm. Recurrence within 1 month occurred in 0/9 eyes with BRVO and 4/9 eyes with CRVO, with a significant difference between the two groups(p=0.04).

Conclusion:IVRBS was associated with fewer recurrences within 1 month after the first injection in BRVO compared to that observed for CRVO, suggesting that IVRBS is effective for the short-term treatment of BRVO. Visual acuity improved at 3 months after the first injection in BRVO, but not in CRVO, suggesting the need for a longer-term study.


Copyright © 2025, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有